Abente Eugenio J, Subramanian Murugan, Ramachandran Vimal, Najafi-Shoushtari S Hani
Department of Cell and Developmental Biology, Weill Cornell Medical College, Cornell University, New York 10021, NY, USA; Weill Cornell Medical College-Qatar, Qatar Foundation, Education City, P.O. Box 24144, Doha, Qatar.
Department of Cell and Developmental Biology, Weill Cornell Medical College, Cornell University, New York 10021, NY, USA; Weill Cornell Medical College-Qatar, Qatar Foundation, Education City, P.O. Box 24144, Doha, Qatar.
Arch Biochem Biophys. 2016 Jan 1;589:108-19. doi: 10.1016/j.abb.2015.09.018. Epub 2015 Sep 26.
The emergence of a worldwide obesity epidemic has dramatically increased the prevalence of insulin resistance and metabolic syndrome, predisposing individuals to a greater risk for the development of non-alcoholic fatty liver disease, type II diabetes and atherosclerotic cardiovascular diseases. Current available pharmacological interventions combined with diet and exercise-based managements are still poorly effective for weight management, likely in part due to an incomplete understanding of regulatory mechanisms and pathways contributing to the systemic metabolic abnormalities under disturbed energy homeostasis. MicroRNAs, small non-coding RNAs that regulate posttranscriptional gene expression, have been increasingly described to influence shifts in metabolic pathways under various obesity-related disease settings. Here we review recent discoveries of the mechanistic role that microRNAs play in regulating metabolic functions in liver and adipose tissues involved in obesity associated disorders, and briefly discusses the potential candidates that are being pursued as viable therapeutic targets.
全球肥胖流行的出现显著增加了胰岛素抵抗和代谢综合征的患病率，使个体患非酒精性脂肪性肝病、II型糖尿病和动脉粥样硬化性心血管疾病的风险更高。目前可用的药物干预措施与基于饮食和运动的管理方法相结合，在体重管理方面仍然效果不佳，这可能部分是由于对能量稳态紊乱下导致全身代谢异常的调节机制和途径的理解不完整。微小RNA是调节转录后基因表达的小型非编码RNA，越来越多的研究表明，它在各种肥胖相关疾病背景下影响代谢途径的转变。在此，我们综述了微小RNA在调节与肥胖相关疾病有关的肝脏和脂肪组织代谢功能中所起机制作用的最新发现，并简要讨论了作为可行治疗靶点正在研究的潜在候选物。
